Chantix
Product Images NDC 68151-4953

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Chantix (NDC 68151-4953). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (68151 4953)

Label for CHANTIX 0.5 mg tablet, showing the active ingredient varenicline. The manufacturer is Pfizer. The label includes lot number D10145534 and expiration date 07/14. It also shows the product NDC 68151-4953 and barcode for Rx only packaging.*

FDA Label Image

Chemical Structure (Chantix 01)

Chemical structure diagram showing two molecular components. One component resembles a bicyclic structure with a positively charged amine group, and the other a side chain with hydroxyl and carboxyl groups. The image likely represents the chemical structure of the active ingredient related to CHANTIX.*

FDA Label Image

Figure 1 (Chantix 02)

A bar chart comparing different dosages and formulations of CHANTIX, including 0.5 mg and 1.0 mg doses, along with placebo and bupropion SR 150 mg BID. The chart shows results from multiple studies (Study 2 through Study 5) with percentage values on the y-axis, likely representing a measured outcome across treatment groups.*

FDA Label Image

Figure 2 (Chantix 03)

A bar chart comparing the percentages of a variable across different studies (Study 2 to Study 5) and treatment groups including CHANTIX at doses 0.5 mg, 1.0 mg, and 1.0 mg with additional dosing, versus placebo. The chart includes error bars for each group, with the y-axis representing percentage values from 0% to 35%.*

FDA Label Image

Figure 3 (Chantix 04)

A line graph showing percent continuous abstinent over time in weeks for CHANTIX 1.0 mg BID compared to placebo. The x-axis represents non-treatment follow-up in weeks, and the y-axis shows percent continuous abstinent. CHANTIX shows a higher percentage of continuous abstinent participants over time compared to placebo.*

FDA Label Image

Company Logo (Chantix 05)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.